Literature DB >> 11389545

Quantitative nuclear grade (QNG): a new image analysis-based biomarker of clinically relevant nuclear structure alterations.

R W Veltri1, A W Partin, M C Miller.   

Abstract

This review addresses the potential clinical value of using quantitative nuclear morphometry information derived from computer-assisted image analysis for cancer detection and predicting outcomes such as tumor stage, recurrence, and progression. Today's imaging technology uses sophisticated hardware platforms coupled with powerful and user-friendly software packages that are commercially available as complete image analysis systems. There are many different mathematically derived nuclear morphometric descriptors (NMD's) (i.e. texture features) that can be calculated by these image analysis systems, but for the most part, these NMD's quantify nuclear size, shape, DNA content (ploidy), and chromatin organization (i.e. texture, both Markovian and non-Markovian) parameters. We have utilized commercially available image analysis systems and the NMD's calculated by these systems to create a mathematical solution, termed quantitative nuclear grade (QNG), for making clinical, diagnostic, and prognostic outcome predictions in both prostate and bladder cancer. A separate computational model is calculated for each outcome of interest using well-characterized and robust training, testing, and validation patient sample sets that adequately represent the selected population and clinical dilemma. A specific QNG solution may be calculated either by non-parametric statistical methods or non-linear mathematics employed by artificial neural networks (ANNs). The QNG solution, a measure of genomic instability, provides a unique independent variable to be used alone or to be included in an algorithm to assess a specific clinical outcome. This approach of customization of the nuclear morphometric descriptor (NMD) information through the calculation of a QNG solution mathematically adjusts for redundancy of features and reduces the complexity of the inputs used to create decision support tools for patient disease management. J. Cell. Biochem. Suppl. 35:151-157, 2000. Copyright 2001 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11389545     DOI: 10.1002/1097-4644(2000)79:35+<151::aid-jcb1139>3.0.co;2-7

Source DB:  PubMed          Journal:  J Cell Biochem Suppl        ISSN: 0733-1959


  14 in total

1.  Quantitative characterization of preneoplastic progression using single-cell computed tomography and three-dimensional karyometry.

Authors:  Vivek Nandakumar; Laimonas Kelbauskas; Roger Johnson; Deirdre Meldrum
Journal:  Cytometry A       Date:  2011-01       Impact factor: 4.355

2.  Quantification of diverse subcellular immunohistochemical markers with clinicobiological relevancies: validation of a new computer-assisted image analysis procedure.

Authors:  Marylène Lejeune; Joaquín Jaén; Lluis Pons; Carlos López; Maria-Teresa Salvadó; Ramón Bosch; Marcial García; Patricia Escrivà; Jordi Baucells; Xavier Cugat; Tomás Alvaro
Journal:  J Anat       Date:  2008-06       Impact factor: 2.610

3.  Automated prostate tissue referencing for cancer detection and diagnosis.

Authors:  Jin Tae Kwak; Stephen M Hewitt; André Alexander Kajdacsy-Balla; Saurabh Sinha; Rohit Bhargava
Journal:  BMC Bioinformatics       Date:  2016-06-01       Impact factor: 3.169

Review 4.  Applications of machine learning in drug discovery and development.

Authors:  Jessica Vamathevan; Dominic Clark; Paul Czodrowski; Ian Dunham; Edgardo Ferran; George Lee; Bin Li; Anant Madabhushi; Parantu Shah; Michaela Spitzer; Shanrong Zhao
Journal:  Nat Rev Drug Discov       Date:  2019-06       Impact factor: 84.694

Review 5.  The prognostic molecular markers in hepatocellular carcinoma.

Authors:  Lun-Xiu Qin; Zhao-You Tang
Journal:  World J Gastroenterol       Date:  2002-06       Impact factor: 5.742

6.  Nuclear IMPDH Filaments in Human Gliomas.

Authors:  Narges Ahangari; David G Munoz; Josee Coulombe; Douglas A Gray; Elizabeth C Engle; Long Cheng; John Woulfe
Journal:  J Neuropathol Exp Neurol       Date:  2021-10-26       Impact factor: 3.685

7.  p300 (histone acetyltransferase) biomarker predicts prostate cancer biochemical recurrence and correlates with changes in epithelia nuclear size and shape.

Authors:  Sumit Isharwal; Michael C Miller; Cameron Marlow; Danil V Makarov; Alan W Partin; Robert W Veltri
Journal:  Prostate       Date:  2008-07-01       Impact factor: 4.104

8.  Potential use of quantitative tissue phenotype to predict malignant risk for oral premalignant lesions.

Authors:  Martial Guillaud; Lewei Zhang; Catherine Poh; Miriam P Rosin; Calum MacAulay
Journal:  Cancer Res       Date:  2008-05-01       Impact factor: 12.701

9.  Improved prediction of prostate cancer recurrence through systems pathology.

Authors:  Carlos Cordon-Cardo; Angeliki Kotsianti; David A Verbel; Mikhail Teverovskiy; Paola Capodieci; Stefan Hamann; Yusuf Jeffers; Mark Clayton; Faysal Elkhettabi; Faisal M Khan; Marina Sapir; Valentina Bayer-Zubek; Yevgen Vengrenyuk; Stephen Fogarsi; Olivier Saidi; Victor E Reuter; Howard I Scher; Michael W Kattan; Fernando J Bianco; Thomas M Wheeler; Gustavo E Ayala; Peter T Scardino; Michael J Donovan
Journal:  J Clin Invest       Date:  2007-07       Impact factor: 14.808

10.  Using nuclear morphometry to predict the need for treatment among men with low grade, low stage prostate cancer enrolled in a program of expectant management with curative intent.

Authors:  Danil V Makarov; Cameron Marlow; Jonathan I Epstein; M Craig Miller; Patricia Landis; Alan W Partin; H Ballentine Carter; Robert W Veltri
Journal:  Prostate       Date:  2008-02-01       Impact factor: 4.104

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.